ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 141 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2021. The put-call ratio across all filers is 1.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $155,042 | -68.3% | 97,511 | +24.1% | 0.00% | -100.0% |
| Q4 2022 | $489,479 | +178.1% | 78,568 | +198.8% | 0.00% | – |
| Q3 2022 | $176,000 | +2.3% | 26,293 | -2.5% | 0.00% | – |
| Q2 2022 | $172,000 | +49.6% | 26,968 | +9.0% | 0.00% | – |
| Q1 2022 | $115,000 | +62.0% | 24,744 | +74.8% | 0.00% | – |
| Q4 2021 | $71,000 | -82.9% | 14,155 | -58.8% | 0.00% | -100.0% |
| Q3 2021 | $414,000 | -45.9% | 34,360 | -5.1% | 0.00% | 0.0% |
| Q2 2021 | $765,000 | -30.1% | 36,188 | -7.3% | 0.00% | 0.0% |
| Q1 2021 | $1,095,000 | +7.5% | 39,039 | -0.4% | 0.00% | 0.0% |
| Q4 2020 | $1,019,000 | -30.1% | 39,190 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $1,457,000 | -27.3% | 39,190 | +0.4% | 0.00% | -50.0% |
| Q2 2020 | $2,003,000 | +66.2% | 39,034 | +2.1% | 0.00% | +33.3% |
| Q1 2020 | $1,205,000 | -47.7% | 38,233 | -1.1% | 0.00% | -25.0% |
| Q4 2019 | $2,306,000 | +61.9% | 38,664 | -0.5% | 0.00% | +33.3% |
| Q3 2019 | $1,424,000 | -20.3% | 38,854 | +1.2% | 0.00% | -25.0% |
| Q2 2019 | $1,786,000 | +26.0% | 38,390 | +8.8% | 0.00% | +33.3% |
| Q1 2019 | $1,417,000 | -14.1% | 35,290 | -1.6% | 0.00% | -25.0% |
| Q4 2018 | $1,649,000 | +5.9% | 35,846 | +2.1% | 0.00% | +33.3% |
| Q3 2018 | $1,557,000 | +13.5% | 35,099 | +0.2% | 0.00% | 0.0% |
| Q2 2018 | $1,372,000 | -28.0% | 35,018 | +32.9% | 0.00% | -25.0% |
| Q1 2018 | $1,906,000 | +8.2% | 26,352 | -1.5% | 0.00% | 0.0% |
| Q4 2017 | $1,761,000 | +29.4% | 26,747 | -1.5% | 0.00% | +33.3% |
| Q3 2017 | $1,361,000 | +11.3% | 27,154 | +2.8% | 0.00% | 0.0% |
| Q2 2017 | $1,223,000 | +22.8% | 26,416 | -6.4% | 0.00% | +50.0% |
| Q1 2017 | $996,000 | +170.7% | 28,216 | -4.1% | 0.00% | +100.0% |
| Q4 2016 | $368,000 | -12.4% | 29,416 | -3.0% | 0.00% | 0.0% |
| Q3 2016 | $420,000 | +41.4% | 30,316 | +1.0% | 0.00% | 0.0% |
| Q2 2016 | $297,000 | -36.8% | 30,016 | +8.1% | 0.00% | 0.0% |
| Q1 2016 | $470,000 | -13.3% | 27,765 | +14.0% | 0.00% | 0.0% |
| Q4 2015 | $542,000 | -4.1% | 24,350 | +1.6% | 0.00% | 0.0% |
| Q3 2015 | $565,000 | -71.2% | 23,964 | 0.0% | 0.00% | -80.0% |
| Q2 2015 | $1,959,000 | +73.5% | 23,964 | +96.5% | 0.01% | +66.7% |
| Q1 2015 | $1,129,000 | +144.9% | 12,197 | +7.0% | 0.00% | +200.0% |
| Q4 2014 | $461,000 | +120.6% | 11,397 | +33.3% | 0.00% | 0.0% |
| Q3 2014 | $209,000 | +54.8% | 8,549 | +0.6% | 0.00% | – |
| Q2 2014 | $135,000 | +8.9% | 8,500 | +3.7% | 0.00% | – |
| Q1 2014 | $124,000 | +9.7% | 8,200 | 0.0% | 0.00% | – |
| Q4 2013 | $113,000 | -8.9% | 8,200 | +24.2% | 0.00% | – |
| Q3 2013 | $124,000 | – | 6,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |